L Number	Hits	Search Text	DB	Time stamp
1	1	unoprostone or (isopropyl adj unoprostone)	USPAT; US-PGPUB	2003/09/04 22:35
2	1	"9841208"	DERWENT	2003/09/04 22:11
3	2	reed and (ocular adj hypertension)	DERWENT	2003/09/04 22:11
4	4	reed and (ocular adj hypertension)	US-PGPUB; DERWENT	2003/09/04 22:32
5	1	"5432174" .pn.	US-PGPUB; DERWENT	2003/09/04 22:33
6	1	"5236907" .pn.	US-PGPUB; DERWENT	2003/09/04 22:33
7	55	unoprostone	USPAT; US-PGPUB	2003/09/04 22:35
8	25	(isopropyl adj unoprostone)	USPAT; US-PGPUB	2003/09/04 23:45
9	29	(isopropyl adj unoprostone)	USPAT; US-PGPUB; DERWENT	2003/09/04 22:36
10	15	(isopropyl adj unoprostone) and hypertension	USPAT; US-PGPUB; DERWENT	2003/09/04 22:39
11	1	"200292098"	USPAT; US-PGPUB; DERWENT	2003/09/04 22:41
12	2	"200152876"	USPAT; US-PGPUB; DERWENT	2003/09/04 22:44
13	2	"2001052876"	USPAT; US-PGPUB; DERWENT	2003/09/04 22:42
14	2	"5075334" .pn.	USPAT; US-PGPUB; DERWENT	2003/09/04 22:46
15	2	"5166175" .pn.	USPAT; US-PGPUB; DERWENT	2003/09/04 22:47
16	3	"3678092" .pn.	USPAT; US-PGPUB; DERWENT	2003/09/04 22:47
17	2	"5397797" .pn.	USPAT; US-PGPUB; DERWENT	2003/09/04 22:48
18	2	"5994397" .pn.	USPAT; US-PGPUB; DERWENT	2003/09/04 22:48
19	479	(514/530).ccls.	USPAT; US-PGPUB	2003/09/04 23:47
20	1	((514/530).ccls.) and unoproston	USPAT; US-PGPUB	2003/09/04 23:46
21	0	((514/530).ccls.) and unoprostone	USPAT; US-PGPUB	2003/09/04 23:46
22	55	unoprostone	USPAT; US-PGPUB	2003/09/04 23:46
23	166	(514/573).ccls.	USPAT; US-PGPUB	2003/09/04 23:47
24	0	((514/573).ccls.) and unoprostone	USPAT; US-PGPUB	2003/09/04 23:47
25	0	((514/573).ccls.) and unoproston	USPAT; US-PGPUB	2003/09/04 23:47
-	28	opening adj potassium adj channel	USPAT; US-PGPUB	2003/09/04 19:40
-	195	hyperpolarization adj2 cell	USPAT; US-PGPUB	2003/09/04 19:40
-	72	(hyperpolarization adj2 cell) and (induce or inducing or cause or causing)	USPAT; US-PGPUB	2003/09/04 19:43
-	19	((hyperpolarization adj2 cell) and (induce or inducing or cause or causing)) not potassium	USPAT; US-PGPUB	2003/09/04 21:53

```
      (FILE 'HOME' ENTERED AT 21:54:43 ON 04 SEP 2003)

      FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS, USPATFULL' ENTERED AT 21:55:31 ON
      04 SEP 2003
L1           359 S 120373-24-2/RN OR ISOPROPYL UNOPROSTONE
L2           143 S L1/THUR
L3           143 FOCUS L2 1-
L4            52 S L3 AND (HYPERTENSION OR PULMONARY HYPERTENSION OR ASTHMA OR
L5            52 FOCUS L4 1-

=> dup rem l5
PROCESSING COMPLETED FOR L5
L6            45 DUP REM L5 (7 DUPLICATES REMOVED)

=> d ibib abs 1-45

L6   ANSWER 1 OF 45  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2003:633448  CAPLUS
TITLE:                    Coated pharmaceutical tablets with speckled appearance
INVENTOR(S):              Martino, Alice C.; Noack, Robert M.; Pierman, Steven
                          A.
PATENT ASSIGNEE(S):       Pharmacia Corporation, USA
SOURCE:                   PCT Int. Appl., 30 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

      PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
      ----------------  ----  --------       ---------------  --------
      WO 2003066030      A2   20030814       WO 2003-US3837   20030206
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
              UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
              CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
              NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
              ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                    US 2002-355705P  P  20020207
AB   A pharmaceutical tablet is provide comprising a core and a coating
     adherent thereto, wherein (a) the core comprises solid particles of a
     water-sol. dye distributed in a matrix and (b) the coating comprises
     gellan gum.  The tablet is suitable for peroral or intraoral
     administration, for example for delivery of a drug contained in the core
     of the tablet to a subject.  The tablet has a speckled appearance that
     renders the tablet readily identifiable.

L6   ANSWER 2 OF 45  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2003:633447  CAPLUS
TITLE:                    Pharmaceutical dosage form for mucosal delivery
INVENTOR(S):              Martino, Alice C.; Pierman, Steven A.; Noack, Robert
                          M.; Britten, Nancy
PATENT ASSIGNEE(S):       Pharmacia Corporation, USA
SOURCE:                   PCT Int. Appl., 34 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003066029	A2	20030814	WO 2003-US3836	20030206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-355703P P 20020207

AB A pharmaceutical tablet is provided comprising an intraorally disintegratable core and an excipient coating adherent thereto, wherein the coating comprises gellan gum. The tablet is suitable for intraoral administration, for example for delivery of a drug contained in the core of the tablet to a subject, at least in part by absorption of the drug via oral mucosa of the subject.

L6 ANSWER 3 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2003:220322 USPATFULL

TITLE: Ophthalmic compositions for treating ocular **hypertension**

INVENTOR(S): Garcia, Maria L., Edison, NJ, UNITED STATES
Kaczorowski, Gregory J., Edison, NJ, UNITED STATES
McManus, Owen B., Rahway, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003153613	A1	20030814
APPLICATION INFO.:	US 2003-361666	A1	20030210 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-764738, filed on 17 Jan 2001, GRANTED, Pat. No. US 6545036

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-176695P	20000118 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 801
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2003:188559 USPATFULL

TITLE: Chloride channel opener

INVENTOR(S): Ueno, Ryuji, Montgomery, MD, UNITED STATES
Cuppoletti, John, Cincinnati, OH, UNITED STATES

PATENT ASSIGNEE(S): SUCAMPO, A.G. (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2003130352	A1	20030710
APPLICATION INFO.:	US 2002-231341	A1	20020830 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-315917P	20010831 (60)
	US 2002-372104P	20020415 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SUGHRUE MION, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC, 20037-3213
NUMBER OF CLAIMS: 32
EXEMPLARY CLAIM: 1
LINE COUNT: 1420
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a novel use of a prostaglandin compound as a chloride channel opener. According to the instant invention, chloride channels in a mammalian subject can be opened by a prostaglandin compound to facilitate chloride ion transportation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2003:24236 USPATFULL
TITLE: Treatment
INVENTOR(S): Richardson, HelenE, Uppsala, SWEDEN
Zimmerman, Thom J., Louisville, KY, UNITED STATES
Challoner, Teresa, London, UNITED KINGDOM
Jonsson, Per, Uppsala, SWEDEN
Gronbladh, Anna, Enskede, SWEDEN
Ohagen, Patrik, Uppsala, SWEDEN
Gieseker, Donald, Bucks, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003018079	A1	20030123
APPLICATION INFO.:	US 2001-35963	A1	20011109 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-248123P	20001113 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DINSMORE & SHOHL, LLP, 1900 CHEMED CENTER, 255 EAST FIFTH STREET, CINCINNATI, OH, 45202
NUMBER OF CLAIMS: 75
EXEMPLARY CLAIM: 1
LINE COUNT: 635
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to using two or more agents in combination with capacity of reducing the intraocular pressure in a therapy with an improved efficacy to treat advanced glaucoma in such patients who suffer from detectable vision related impairments, when said agents are administered simultaneously. The combined use will also find advantage in treatment of individuals in need of a high IOP-reduction, such as those being exposed to risk factors rendering them susceptible to visual impairments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2002:965141 CAPLUS
DOCUMENT NUMBER: 138:19542

TITLE: Prostanoid therapies for the treatment of glaucoma
INVENTOR(S): Robertson, Stella M.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Provisional Ser. No. 50,963.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002193441	A1	20021219	US 2002-80364	20020221

PRIORITY APPLN. INFO.: US 2001-270228P P 20010221
AB Compns. and methods for the treatment of glaucoma and/or ocular **hypertension** in humans utilizing improved doses of certain prostaglandin derivs. and analogs are disclosed.

L6 ANSWER 7 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2002:717100 CAPLUS
DOCUMENT NUMBER: 137:226656
TITLE: Method for opening potassium channels
INVENTOR(S): Lambrou, George N.; Ottlecz, Anna; Percicot, Christine; Wiederholt, Michael
PATENT ASSIGNEE(S): Fr.
SOURCE: U.S. Pat. Appl. Publ., 7 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002133009	A1	20020919	US 2002-90085	20020304

PRIORITY APPLN. INFO.: US 2001-275316P P 20010313
OTHER SOURCE(S): MARPAT 137:226656
AB The present invention relates to a method for opening potassium channels in mammalian cells by administering to a mammal effective amts. of potassium channel-opening keto compds. as described herein. Furthermore, the present invention relates to a method of maintaining or inducing hyperpolarization of the cell membrane which comprises administering an effective amt. of a potassium channel opening keto compd. as disclosed herein. The present invention further relates to a method for treating conditions and disease states related to potassium channel function which comprises administering an effective amt. of a potassium channel opening keto compd. disclosed herein.

L6 ANSWER 8 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2002:575766 CAPLUS
DOCUMENT NUMBER: 137:119709
TITLE: Use of nonsteroidal antiinflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular **hypertension**
INVENTOR(S): Hellberg, Mark R.; Nixon, Jon C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 575,833.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002103255	A1	20020801	US 2002-59692	20020128
US 6066671	A	20000523	US 1997-994903	19971219
US 6342524	B1	20020129	US 2000-575833	20000522

PRIORITY APPLN. INFO.: US 1997-994903 A2 19971219
US 2000-575833 A2 20000522

OTHER SOURCE(S): MARPAT 137:119709

AB Methods and compns. are disclosed for the treatment of glaucoma and ocular **hypertension**, comprising the administration of a prostaglandin FP receptor agonist (e.g. travoprost)and a prostaglandin synthesis inhibitor (e.g. nepafenac).

L6 ANSWER 9 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2002:143289 CAPLUS
DOCUMENT NUMBER: 136:178021
TITLE: Treatment of ocular **hypertension** and glaucoma with prostaglandin related compounds
INVENTOR(S): Ueno, Ryuji
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. Ser. No. 817,046.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002022644	A1	20020221	US 2001-900021	20010709
US 6458836	B2	20021001		
US 2001034355	A1	20011025	US 2000-730830	20001207
US 2001056104	A1	20011227	US 2001-817046	20010327

PRIORITY APPLN. INFO.: US 2000-527573 B2 20000316
US 2000-730830 A2 20001207
US 2001-817046 A2 20010327

OTHER SOURCE(S): MARPAT 136:178021

AB Disclosed is treatment of ocular **hypertension** and glaucoma by long-term therapy with a prostaglandin related compd. for eliminating or reducing potential iridic pigmentation. Compn. useful for the treatment, and use of the prostaglandin related compd. for producing the compn. are also disclosed.

L6 ANSWER 10 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2002:11105 CAPLUS
DOCUMENT NUMBER: 136:90949
TITLE: Compositions containing isopropyl unoprostone for reducing ocular **hypertension**
INVENTOR(S): Reed, Kenneth Warren; Yen, Shau Fong; Sou, Mary; Peacock, Regina Flinn
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 42,817, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002002185	A1	20020103	US 2001-812162	20010319

PRIORITY APPLN. INFO.: US 1997-93065P P 19970317
US 1998-42817 B2 19980317

GI



I

AB An improved ophthalmic compn., includes docosanoid active agents, which are esp. useful in lowering intraocular pressure assocd. with glaucoma. Improvements in IOP redn. efficacy, preservative efficacy and reduced additive concns. are achieved by utilizing the disclosed compns. which include a docosanoid active agent (e.g., iso-Pr unoprostone, I), in conjunction with selected nonionic surfactants, preservatives, and nonionic tonicity adjusting agents.

L6 ANSWER 11 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:888567 CAPLUS
DOCUMENT NUMBER: 137:363114
TITLE: Method for treating ocular **hypertension** and glaucoma with eye drops contg. 15-keto-prostaglandins
INVENTOR(S): Ueno, Ryuji
PATENT ASSIGNEE(S): Sucampo AG, Switz.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002092098	A1	20021121	WO 2002-JP4600	20020513

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-290355P P 20010514
OTHER SOURCE(S): MARPAT 137:363114
AB A method for treating ocular **hypertension** and glaucoma, which comprises an administration of eye drops comprising a 15-keto-prostaglandin compd. as an active ingredient to a subject in need of such treatment in a single administration vol. of at least 20 .mu.mL/eye is disclosed. According to the present method, the intraocular pressure reducing effect of the compd. is surprisingly augmented.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:832623 CAPLUS
DOCUMENT NUMBER: 137:316113
TITLE: Prostaglandins in combination with NO-donating

compounds for lowering ocular tension
INVENTOR(S): Orihashi, Masahiro; Koike, Junpei; Masuda, Kanako
PATENT ASSIGNEE(S): Teika Pharmaceutical Co., Ltd., Japan; Kowa Co., Ltd.
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085372	A1	20021031	WO 2002-JP3292	20020402

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2001-121295 A 20010419
AB It is intended to provide medicines having an ocular tension-lowering effect on ocular **hypertension** and glaucoma. Because of showing an excellent effect of lowering ocular tension, medicines comprising a combination of a prostaglandin compd. with an NO-donating compd. are useful in treating ocular **hypertension** and glaucoma. For example, an eyedrop kit for the treatment of glaucoma contained an aq. soln. (100 mL) contg. 0.25 % nipradilol and an aq. soln. (100 mL) contg. 0.005 % latanoprost.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:716095 CAPLUS
DOCUMENT NUMBER: 137:226650
TITLE: Improved prostanoid therapies for the treatment of glaucoma
INVENTOR(S): Robertson, Stella M.
PATENT ASSIGNEE(S): Alcon Universal Ltd., Switz.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072105	A2	20020919	WO 2002-US5130	20020221
WO 2002072105	A3	20030417		

W: AU, BR, CA, CN, JP, KR, MX, PH, PL, US, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR

PRIORITY APPLN. INFO.: US 2001-270228P P 20010221
AB The invention discloses the use of certain prostaglandin derivs. and analogs for the treatment of glaucoma and/or ocular **hypertension** in humans. The invention also discloses the compns. and improved doses of drugs for glaucoma therapy.

L6 ANSWER 14 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:594810 CAPLUS

DOCUMENT NUMBER: 137:155177
TITLE: Preparation and ophthalmic compositions of amino acid amides for treating ocular **hypertension**
INVENTOR(S): Garcia, Maria L.; Kaczorowski, Gregory J.; Gao, Ying-Duo
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060863	A1	20020808	WO 2002-US3049	20020124

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-264954P P 20010130
OTHER SOURCE(S): MARPAT 137:155177
GI



I



II

AB The compds. with a general formula of I [wherein R and R2 = independently alkyl, (CH2)n(hetero)aryl, (CH2)nheterocycloalkyl, said alkyl or (hetero)aryl optionally substituted with 1-3 groups of R3; Y = (CH2)nSCOR4; X = CH2 or O in which m = 1; R3 = H, alkoxy, alkyl(amino), CF3, NO2, NH2, CN, or halo; R4 = alkoxy or alkyl; R7 = H, halo, OH, NO2, NH2, CN, alkoxycarbonyl, CO2H, haloalkyl, alkoxycarbonylalkyl, or alkylsulfonyl; m = 1-3; n = 0-3; or a pharmaceutically acceptable salt, enantiomer, diastereomer, or mixt. thereof] were prepd. For example,

L-leucine deriv. II was prepd. in a 7-step synthesis involving condensation of 4-phenyl-2-(acetylthiomethyl)butyric acid and (S)-leucine t-Bu ester and amidation with aniline (50%). This invention relates to the use of potent potassium channel blockers or formulations thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compds. to provide a neuroprotective effect to the eye of mammalian species, particularly humans. The compds. I were found to cause concn. dependent inhibition of the fluorescence ratio with IC50 values in the range of 10 nM to 5 .mu.M, more preferably from 100 nM to 1 .mu.M.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:594635 CAPLUS
DOCUMENT NUMBER: 137:119674
TITLE: Use of prostaglandin F analogs for treatment of cardiac conditions
INVENTOR(S): Stewart, William C.
PATENT ASSIGNEE(S): Pharmaceutical Research Corporation, USA
SOURCE: PCT Int. Appl., 6 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060387	A2	20020808	WO 2002-US3103	20020130
WO 2002060387	A3	20030306		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-265262P P 20010130

AB Methods are provided for the amelioration of cardiac conditions using PGF analogs which lack affinity for prostaglandin receptors. Systemic administration of at least one PGF analog, preferably unoprostone iso-Pr ester, provides both therapeutic and prophylactic treatment for such conditions as congestive **heart failure**.

L6 ANSWER 16 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2002:179191 USPATFULL
TITLE: Ophthalmic compositions for treating ocular **hypertension**
INVENTOR(S): Ponticello, Gerald S., Lansdale, PA, UNITED STATES
Sugrue, Michael F., Blue Bell, PA, UNITED STATES
PATENT ASSIGNEE(S): Merck & Co., Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002094981	A1	20020718
APPLICATION INFO.:	US 2001-23336	A1	20011217 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-677100, filed on 29 Sep 2000, PENDING Continuation of Ser. No. US 1998-86829, filed on 29 May 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-48140P	19970530 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Merck & Co., Inc., Patent Department, P.O. Box 2000 - RY60-30, Rahway, NJ, 07065-0907
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Combinations of a prostaglandin or an opthalmologically acceptable salt thereof and a topical carbonic anhydrase inhibitor or an opthalmologically acceptable salt thereof are particularly useful in the treatment of ocular **hypertension** and glaucoma. The combinations are characterized by an improved effect and reduced side-effects.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 17 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2002:112316 USPATFULL
TITLE: Stable ophthalmic preparation
INVENTOR(S): Wong, Michelle Pik-Han, Duluth, GA, UNITED STATES
Yen, Shau-Fong, Atlanta, GA, UNITED STATES
Sou, Mary, Alpharetta, GA, UNITED STATES
Minick, Kasey Jon, Alpharetta, GA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002058049	A1	20020516	
APPLICATION INFO.:	US 2001-952294	A1	20010914	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-232316P	20000914 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 268
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a stable method for storing a pharmaceutical composition containing a prostaglandin-like-compound. The method has the step of storing the composition in a polypropylene container.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 18 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2002:175189 USPATFULL
TITLE: Ocular hypotensive agents
INVENTOR(S): Ueno, Ryuzo, Nishinomiya, JAPAN
Ueno, Ryuji, Nishinomiya, JAPAN
Oda, Tomio, Sanda, JAPAN
PATENT ASSIGNEE(S): Sucampo Pharmaceuticals, Inc., Bethesda, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 6420422 B1 20020716
APPLICATION INFO.: US 1995-476583 19950607 (8)
RELATED APPLN. INFO.: Division of Ser. No. US 1993-161449, filed on 6 Dec 1993 Continuation of Ser. No. US 1992-931969, filed on 19 Aug 1992, now abandoned Continuation of Ser. No. US 1991-774750, filed on 11 Oct 1991, now patented, Pat. No. US 5236907 Division of Ser. No. US 1989-414331, filed on 29 Sep 1989, now abandoned Division of Ser. No. US 1991-760269, filed on 16 Sep 1991, now patented, Pat. No. US 5166178 Division of Ser. No. US 1990-584669, filed on 19 Sep 1990, now patented, Pat. No. US 5151444 Continuation of Ser. No. US 1988-246059, filed on 19 Sep 1988, now patented, Pat. No. US 5001153

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1987-235890	19870918
	JP 1987-334037	19871229
	JP 1988-248720	19881001
	JP 1988-248721	19881001

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Sughrue Mion, PLLC
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an ocular hypotensive composition and a composition for treatment of glaucoma which comprising an amount of 20-substituted-PGs or 20-substituted 15-keto-PGs effective as an ocular hypotensive agent; these compounds exhibit no or little side effect such as transient ocular hypertensive response, hyperemia of conjunctiva or of iris, dacryops, lema, closed eye and the like.

The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 19 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:659772 CAPLUS
DOCUMENT NUMBER: 137:210293
TITLE: Safety of unoprostone isopropyl as mono- or adjunctive therapy in patients with primary open-angle glaucoma or ocular **hypertension**
AUTHOR(S): de Arruda Mello, Paulo Augusto; Yannoulis, Natalia C.; Haque, Reza M.
CORPORATE SOURCE: Department of Ophthalmology, Federal University of Sao Paulo-Paulista School of Medicine and Director Residency Training, Sao Paulo, Brazil
SOURCE: Drug Safety (2002), 25(8), 583-597
CODEN: DRSAEA; ISSN: 0114-5916
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB This review summarizes the safety of unoprostone iso-Pr (both at the 0.12 and 0.15% concns.) instilled twice daily in patients with primary open-angle glaucoma (POAG) or ocular **hypertension** (OH). For unoprostone 0.15%, combined data from two 12-mo comparative monotherapy studies are reported, as well as data from three adjunctive therapy studies and two special population studies. With unoprostone monotherapy,

most adverse events were mild or moderate and transient in nature. Less than 7% of unoprostone-treated patients discontinued therapy due to an adverse event. The most common adverse events assocd. with unoprostone were burning/stinging, burning/stinging directly upon drug instillation, ocular itching, and conjunctival hyperemia. Unoprostone had no clin. notable effects on vital signs, lab. profiles, or comprehensive ophthalmic examns. One of 659 unoprostone 0.15%-treated patients had a change in iris color after 12 mo of monotherapy. Except for a higher incidence of burning/stinging and burning/stinging upon instillation, unoprostone was comparable to timolol 0.5% twice daily and betaxolol 0.5% twice daily. No safety concerns were raised with use of unoprostone as adjunctive therapy. Unoprostone had no significant effect on exercise-induced heart rate in healthy subjects or on pulmonary function in patients with mild-to-moderate **asthma**. The safety profile of unoprostone 0.15% was consistent with published information on the 0.12% formulation. In conclusion, unoprostone has an excellent safety profile in patients with POAG or OH.

REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 6
ACCESSION NUMBER: 2001:936093 CAPLUS
DOCUMENT NUMBER: 136:48478
TITLE: Treatment of ocular **hypertension** and glaucoma
INVENTOR(S): Ueno, Ryuji
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Appl. 2001 34,355.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001056104	A1	20011227	US 2001-817046	20010327
US 2001034355	A1	20011025	US 2000-730830	20001207
US 2002022644	A1	20020221	US 2001-900021	20010709
US 6458836	B2	20021001		

PRIORITY APPLN. INFO.: US 2000-527573 B2 20000316
US 2000-730830 A2 20001207
US 2001-817046 A2 20010327

AB Disclosed is treatment of ocular **hypertension** and glaucoma by long-term therapy with a prostaglandin related compd. for eliminating or reducing potential iridic pigmentation. Compn. useful for the treatment, and use of the prostaglandin related compd. for producing the compn. are also disclosed.

L6 ANSWER 21 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 7
ACCESSION NUMBER: 2001:781463 CAPLUS
DOCUMENT NUMBER: 135:327373
TITLE: Prostaglandin-related compounds for the treatment of ocular **hypertension**
INVENTOR(S): Ueno, Ryuji
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 527,573, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001034355	A1	20011025	US 2000-730830	20001207
WO 2001068072	A2	20010920	WO 2001-JP2035	20010315
WO 2001068072	A3	20020606		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1272194	A2	20030108	EP 2001-912374	20010315

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001009192	A	20030527	BR 2001-9192	20010315
US 2001056104	A1	20011227	US 2001-817046	20010327
US 2002022644	A1	20020221	US 2001-900021	20010709
US 6458836	B2	20021001		
NO 2002004381	A	20021115	NO 2002-4381	20020913

PRIORITY APPLN. INFO.:	US 2000-527573	B2	20000316
	US 2000-730830	A	20001207
	WO 2001-JP2035	W	20010315
	US 2001-817046	A2	20010327

OTHER SOURCE(S): MARPAT 135:327373

AB The invention discloses treatment of ocular **hypertension** by long-term therapy with a prostaglandin-related compd. for eliminating or reducing potential iridic pigmentation.

L6 ANSWER 22 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	2001:545509 CAPLUS
DOCUMENT NUMBER:	135:127213
TITLE:	Ophthalmic compositions containing potassium channel blockers for treating ocular **hypertension**
INVENTOR(S):	Garcia, Maria L.; Kaczorowski, Gregory J.; McManus, Owen B.
PATENT ASSIGNEE(S):	Merck & Co., Inc., USA
SOURCE:	PCT Int. Appl., 39 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052876	A1	20010726	WO 2001-US1623	20010117

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2001044460	A1	20011122	US 2001-764738	20010117
US 6545036	B2	20030408		
EP 1251862	A1	20021030	EP 2001-903102	20010117

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2003520245	T2	20030702	JP 2001-552923		20010117
US 2003153613	A1	20030814	US 2003-361666		20030210
PRIORITY APPLN. INFO.:			US 2000-176695P	P	20000118
			US 2001-764738	A3	20010117
			WO 2001-US1623	W	20010117

OTHER SOURCE(S): MARPAT 135:127213

AB This invention relates to the use of potent potassium channel blockers or a formulation in the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compds. to provide a neuroprotective effect to the eye, particularly in humans. Thus, a potassium channel blocker was prepd. by the treatment of indomethacin with dicyclohexylcarbodiimide in THF soln. The compd. was applied to the intracellular side of the channel at 0.001-10 .mu.M. The compd. reduced channel open probability. The IC50 for block of maxi-K channels was 0.5-300 nM.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:217890 CAPLUS

DOCUMENT NUMBER: 134:242691

TITLE: Eye drops for the treatment of glaucoma and ocular **hypertension**

INVENTOR(S): Shiratori, Kenji; Hashimoto, Mitsumasa; Toyota, Yoshihiro; Matsukawa, Hidehiko; Koguma, Toru; Ezure, Yoji; Tsuritani, Masataka

PATENT ASSIGNEE(S): Wakamoto Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001081048	A2	20010327	JP 1999-256920	19990910
PRIORITY APPLN. INFO.:			JP 1999-256920	19990910

AB This invention relates to eye drops comprising .beta.-blockers and intraocular pressure-lowering agents (except .beta.-blockers) in a base which induces liq.-gel transition on the surface of eyes. The eye drops provide long-lasting ocular hypotensive effects with little side effects. Eye drops contg. timolol maleate and dorzolamide in a base contg. Me cellulose, PEG, and Na citrate significantly reduced an intraocular pressure in rabbits.

L6 ANSWER 24 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2001:212463 USPATFULL

TITLE: Ophthalmic compositions for treating ocular **hypertension**

INVENTOR(S): Garcia, Maria L., Edison, NJ, United States
Kaczorowski, Gregory J., Edison, NJ, United States
McManus, Owen B., Skillman, NJ, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001044460	A1	20011122	
	US 6545036	B2	20030408	
APPLICATION INFO.:	US 2001-764738	A1	20010117	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-176695P	20000118	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MERCK AND CO INC, P O BOX 2000, RAHWAY, NJ, 070650907
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
LINE COUNT: 804
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 25 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2001:226680 USPATFULL
TITLE: Method for treating ocular **hypertension** of glaucoma
INVENTOR(S): Ueno, Ryuji, Hyogo, Japan
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6329426	B1	20011211
APPLICATION INFO.:	US 1998-220847		19981228 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1998-JP4399, filed on 30 Sep 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1997-278540	19971013

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB By combined administration of a non-FP receptor agonist type prostaglandin compound, for example isopropyl unoprostone, and a FP-receptor type prostaglandin compound, for example Latanoprost, the ocular hypotensive effect of the prostaglandin compounds is enhanced synergistically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 26 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:163333 CAPLUS
DOCUMENT NUMBER: 134:320839
TITLE: Additive efficacy of unoprostone isopropyl 0.12% (rescula) to latanoprost 0.005%
AUTHOR(S): Stewart, W. C.; Sharpe, E. D.; Stewart, J. A.; Holmes, K. T.; Latham, K. E.
CORPORATE SOURCE: Pharmaceutical Research Corporation, Charleston, SC, USA
SOURCE: American Journal of Ophthalmology (2001), 131(3), 339-344
CODEN: AJOPAA; ISSN: 0002-9394
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal

LANGUAGE: English

AB The purpose of the study was to evaluate the safety and efficacy of adding unoprostone iso-Pr 0.12% vs. placebo both given twice daily to latanoprost 0.005% given every evening. The authors treated 41 patients with primary open-angle glaucoma or ocular **hypertension** with latanoprost 0.005% for 1 mo and then randomized each to either placebo or unoprostone iso-Pr 0.12% for 8 wk. Diurnal intraocular pressures were measured at 08:00, 10:00, 12:00, 18:00, and 20:00 h, both at baseline (time of randomization) and after 8 wk of treatment. Twenty patients were treated in the placebo group and 21 in the unoprostone iso-Pr group. After 8 wk of treatment in the placebo group, the trough intraocular pressure at 08:00 and the diurnal pressure were 20.4.+-.3.2 and 19.1.+-.2.2 mm Hg, resp. In the unoprostone iso-Pr group the pressures were 19.4.+-.3.3 and 18.0.+-.1.7 mm Hg (P =.22 and P =.042), resp. However, eyes with a baseline pressure of 22 mm Hg or greater on latanoprost had an av. 3.3 mm Hg greater redn. at trough (P <.01) and a 2.1 mm Hg greater decrease in diurnal pressure (P =.030) after adding unoprostone iso-Pr (n = 14 eyes) compared with placebo (n = 16 eyes; P <.001). In addn., the range of the pressures throughout the diurnal curve was reduced from 2.7 mm Hg on latanoprost alone to 1.4 mm Hg after adding unoprostone iso-Pr. Adverse events were similar between groups, and no patients were discontinued because of safety reasons. This study suggests that unoprostone iso-Pr can safely improve the diurnal curve characteristics in patients who continue to have an elevated pressure on latanoprost 0.005% alone.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:456889 CAPLUS

DOCUMENT NUMBER: 133:79364

TITLE: Drug compositions for the treatment of ocular **hypertension** or glaucoma

INVENTOR(S): Ueno, Ryuji

PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Japan

SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000038689	A1	20000706	WO 1998-JP5896	19981225
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2356912	AA	20000706	CA 1998-2356912	19981225
EP 1142576	A1	20011010	EP 1998-961549	19981225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: WO 1998-JP5896 A 19981225

AB Simultaneously using both a non-FP receptor agonist type prostaglandin compd. (such as isopropylunoprostone) and an FP receptor agonist type prostaglandin compd. (such as latanoprost) brings about a synergistically enhanced ocular tension lowering effect.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 28 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:84616 CAPLUS

DOCUMENT NUMBER: 132:141953

TITLE: Ophthalmic compositions containing prostaglandins and carbonic anhydrase inhibitors for treatment of ocular

hypertension

INVENTOR(S): Ponticello, Gerald S.; Sugrue, Michael F.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004899	A1	20000203	WO 1999-US16374	19990720
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2337349	AA	20000203	CA 1999-2337349	19990720
AU 9951144	A1	20000214	AU 1999-51144	19990720
EP 1100491	A1	20010523	EP 1999-935726	19990720
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521333	T2	20020716	JP 2000-560892	19990720

PRIORITY APPLN. INFO.: US 1998-119951 A 19980721
WO 1999-US16374 W 19990720

AB Combinations of a prostaglandin, or its deriv., hypotensive lipids derived from a prostaglandin or prostaglandin deriv. or an ophthalmol. acceptable salt and a topical carbonic anhydrase inhibitors or their salts are particularly useful in the treatment of ocular **hypertension** and glaucoma. The combinations are characterized by an improved effect and reduced side-effects. Thus, a soln. contained (S,S)-(-)-5,6-dihydro-4-ethylamino-6-methyl-4H-thieno-[2,3b]thiopyran-2-sulfonamide-7,7-dioxide monohydrochloride (carbonic anhydrase inhibitor) 22.26, (+)-isopropylfluprostenol (prostaglandin deriv.) 10.0, sodium citrate-2H2O 2.940, benzalkonium chloride 0.075, hydroxyethyl cellulose 5.00, sodium hydroxide qs to ph 6.0, mannitol 16.00, and water for injection qs to 1000 g.

L6 ANSWER 29 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:84614 CAPLUS
DOCUMENT NUMBER: 132:127751
TITLE: Ophthalmic compositions containing carbonic anhydrase inhibitor, .beta.-adrenergic antagonist, and prostaglandin for treating ocular **hypertension**
INVENTOR(S): Ponticello, Gerald S.; Sugrue, Michael F.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004898	A1	20000203	WO 1999-US16143	19990716
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,				

ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2337399	AA	20000203	CA 1999-2337399	19990716
AU 9950011	A1	20000214	AU 1999-50011	19990716
EP 1109546	A1	20010627	EP 1999-934101	19990716
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521332	T2	20020716	JP 2000-560891	19990716

PRIORITY APPLN. INFO.: US 1998-93594P P 19980721
WO 1999-US16143 W 19990716

OTHER SOURCE(S): MARPAT 132:127751

AB Combinations of a carbonic anhydrase inhibitor (0.5-3.0%), a .beta.-adrenergic antagonist (0.1-0.5%), and a prostaglandin or a prostaglandin deriv. (0.03-1.0%) are particularly useful in the treatment of ocular **hypertension** (glaucoma). The combinations are characterized by an improved therapeutic effect and reduced side-effects. E.g., an ophthalmic formulation was prepd. contg. a carbonic anhydrase inhibitor, MK 507, 22.26 g, 13,14-dihydro-15-keto-20-ethyl-PGF2 iso-Pr ester 10 g, (S)-(-)-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate 6.834 g, Na citrate.cntdot.2H2O 2.940 g, benzalkonium chloride 0.075 g, hydroxyethyl cellulose 5.00 g, NaOH as needed for pH = 6.0, mannitol 16.00 g, and water for injection up to 1000 g. The active compds., phosphate buffer salts, benzalkonium chloride, and Polysorbate 80 were added to and suspended or dissolved in water. The pH of the compn. was adjusted to 5.5-6.0 and dild. 30 to vol. The compn. was rendered sterile by filtration through a sterilizing filter.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 30 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:265897 CAPLUS
DOCUMENT NUMBER: 130:272040
TITLE: Remedial composition for intraocular **hypertension** or glaucoma
INVENTOR(S): Ueno, Ryuji
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Japan
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918969	A1	19990422	WO 1998-JP4399	19980930
W: CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 979652	A1	20000216	EP 1998-945530	19980930
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6329426	B1	20011211	US 1998-220847	19981228

PRIORITY APPLN. INFO.: JP 1997-278540 A 19971013
WO 1998-JP4399 W 19980930

AB The invention relates to the use of iso-Pr unoprostone and latanoprost in combination synergistically improves the effect of lowering intraocular tension. Eye lotions contg. iso-Pr unoprostone 0.06 and latanoprost 0.003% are formulated.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 31 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:799987 CAPLUS

DOCUMENT NUMBER: 130:43360
TITLE: Ophthalmic compositions containing carbonic anhydrase inhibitor and prostaglandin for treating ocular **hypertension**
INVENTOR(S): Ponticello, Gerald S.; Sugrue, Michael F.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9853809	A1	19981203	WO 1998-US10606	19980526
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9876943	A1	19981230	AU 1998-76943	19980526
EP 998277	A1	20000510	EP 1998-924874	19980526
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002501533	T2	20020115	JP 1999-500793	19980526
US 2002094981	A1	20020718	US 2001-23336	20011217

PRIORITY APPLN. INFO.:

US 1997-48140P	P	19970530
GB 1997-19842	A	19970918
WO 1998-US10606	W	19980526
US 1998-86829	B1	19980529
US 2000-677100	A1	20000929

AB Combinations of a prostaglandin or an ophthalmol. acceptable salt and a topical carbonic anhydrase inhibitor or its salt are particularly useful in the treatment of ocular **hypertension** and glaucoma. The combinations are characterized by an improved activity and reduced side-effects. Thus, a soln. contained (S,S)-(-)-5,6-dihydro-4-ethylamino-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide-HCl 22.26, 13,140dihydro-15-keto-20-ethyl-PGF2 iso-Pr ester 10.0, sodium citrate-2H2O 2.940, benzalkonium chloride 0.075, hydroxyethyl cellulose 5.00, mannitol 16.00 and water for injection to 1000 g and NaOH qs to pH 6.0.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 32 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:635653 CAPLUS
DOCUMENT NUMBER: 129:265480
TITLE: Compositions and methods for reducing ocular **hypertension**
INVENTOR(S): Reed, Kenneth Warren; Yen, Shau-fong; Sou, Mary; Peacock, Regina Flinn
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841208	A1	19980924	WO 1998-EP1483	19980313

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9870353	A1	19981012	AU 1998-70353		19980313
AU 738781	B2	20010927			
EP 969846	A1	20000112	EP 1998-916948		19980313
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LV, FI					
BR 9808016	A	20000308	BR 1998-8016		19980313
EE 9900410	A	20000417	EE 1999-410		19980313
NZ 337322	A	20010525	NZ 1998-337322		19980313
JP 2001515502	T2	20010918	JP 1998-540126		19980313
RU 2197970	C2	20030210	RU 1999-121641		19980313
ZA 9802188	A	19980917	ZA 1998-2188		19980316
MX 9908471	A	20000228	MX 1999-8471		19990915
NO 9904481	A	19990916	NO 1999-4481		19990916
PRIORITY APPLN. INFO.:			US 1997-819221	A	19970317
			WO 1998-EP1483	W	19980313

AB Disclosed is an improved ophthalmic compn., including prostaglandin active agents, which is esp. useful in lowering intraocular pressure (IOP) assocd. with glaucoma. Improvements in IOP redn. efficacy, preservative efficacy and reduced additive concns. are achieved by utilizing the disclosed compns. which include a prostaglandin active agent (e.g., iso-Pr unoprostone, a metabolite of an F-series prostaglandin), in conjunction with selected non-ionic surfactants, preservatives, and non-ionic tonicity adjusting agents. An eye soln. contained iso-Pr unoprostone 0.18, Polysorbate-80 0.7, Brij-97 0.3, benzalkonium chlorides 0.011, EDTA 0.02, mannitol 4.7, and distd. water to 100 %. Instillation of .apprx.30 .mu.L of the soln. into the eye of a rabbit resulted in the redn. of IOP to 86 % of the initial IOP.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 33 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:298381 CAPLUS
DOCUMENT NUMBER: 128:289653
TITLE: Prostaglandin-related compound. Isopropyl unoprostone (Rescula)
AUTHOR(S): Azuma, Ikuo
CORPORATE SOURCE: Dep. Ophthalmol., Osaka Med. Coll., Takatsuki, 569-0801, Japan
SOURCE: Atarashii Ganka (1998), 15(4), 469-474
CODEN: ATGAEX; ISSN: 0910-1810
PUBLISHER: Medikaru Ai Shuppan
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese

AB A review with 13 refs., on the structure and intraocular pressure lowering effect of Rescula, and clin. efficacy and adverse effects of Rescula eye drops in treatment of glaucoma and ocular **hypertension**. Effect of Rescula on ocular circulation is also discussed.

L6 ANSWER 34 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:247618 CAPLUS
DOCUMENT NUMBER: 129:23382
TITLE: A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes
AUTHOR(S): Serle, Janet B.; Podos, Steven M.; Kitazawa, Yoshiaki; Wang, Rong-Fang

CORPORATE SOURCE: Dep. Ophthalmology, Mount Sinai Sch. Medicine, New York, NY, 10029, USA
SOURCE: Japanese Journal of Ophthalmology (1998), 42(2), 95-100
CODEN: JJOPA7; ISSN: 0021-5155
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Latanoprost (PxXA41, Xalatan) and iso-Pr unoprostone (UF-021, unoprostone, Rescula) two new prostanoid derivs., have been shown to reduce intraocular pressure (IOP) significantly in patients with glaucoma or ocular **hypertension**. This study was designed to compare the ocular hypotensive effects of latanoprost and unoprostone in cynomologus monkeys with glaucoma and characterizes the prostanoid's mechanisms of action in normal cynomologus monkey eyes. Intraocular pressure was measured daily at 0, 0.5 and 1 h and hourly for 5 addnl. hours during 1 baseline day, 1 vehicle-treated day, and 5 days of therapy with either 0.005% latanoprost or 0.12% unoprostone applied twice daily, at 9:30 am and 3:30 pm, to the glaucomatous eye of eight monkeys with unilateral laser-induced glaucoma. Outflow facility was measured in six normal monkeys 3 h prior to dosing and 1 h after unilateral dosing with either drug. Aq. humor flow rates were measured in six normal monkeys hourly for 4 h on 1 baseline day nd on 1 treatment day beginning 1 h after administration of either drug to one eye. Intraocular pressure was significantly ($P < 0.005$) reduced after the first application for 4 h with latanoprost and for 2 h with unoprostone, up to 5.4 .+-. 0.8 mm Hg (mean .+-. SEM) (latanoprost) and 3.8 .+-. 0.5 mm Hg (unoprostone). Intraocular pressure was significantly ($P < 0.005$) reduced for at least 18 houres following each pm dose of latanoprost. Intraocular pressure was not reduced ($P > 0.05$) 18 h after each pm dose of unoprostone. An enhancement of the ocular hypotensive effect was obsd. from day 1 to 5 with repeated dosing of either drug. Latanoprost produce a greater magnitude of IOP redn. for a longer duration of time than unoprostone after each application. Neither drug altered outflow facility or aq. humor flow rates. Latanoprost and unoprostone appear to reduce IOP in monkey by enhancing uveoscleral outflow. Latanoprost appears to be more efficacious and potent than unoprostone in reducing IOP in glaucomatous monkey eyes.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 35 OF 45 USPATFULL on STN
ACCESSION NUMBER: 96:75413 USPATFULL
TITLE: Treatment of ocular **hypertension** with a synergistic combination
INVENTOR(S): Ueno, Ryuji, Hyogo-ken, Japan
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5547968		19960820
APPLICATION INFO.:	US 1995-487637		19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-352822, filed on 1 Dec 1994, now abandoned which is a continuation of Ser. No. US 1993-51434, filed on 23 Apr 1993, now abandoned which is a continuation of Ser. No. US 1992-833025, filed on 10 Feb 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1991-61328	19910301

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas

NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 650
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for treatment of ocular **hypertension** which comprises ocularly administering, to a subject in need of such treatment, an oculo-hypotensively synergistic combination of

(a) a 15-ketoprostaglandin or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof, and

(b) a carbonate dehydratase inhibitor in an amount effective in treatment of ocular **hypertension**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 36 OF 45 USPATFULL on STN
ACCESSION NUMBER: 95:62725 USPATFULL
TITLE: Treatment of ocular **hypertension**
INVENTOR(S): Ueno, Ryuji, Nishinomiya, Japan
Kuno, Sachiko, Tokyo, Japan
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5432174		19950711
APPLICATION INFO.:	US 1993-162386		19931207 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-933789, filed on 24 Aug 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1992-63316	19920319

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 711
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the treatment of ocular **hypertension** which comprises administering, to a subject in need of such treatment,

(a) a .beta.-adrenergic blocker at the enhancement phase of aqueous humor production, and

(b) a prostanoic acid compound at the suppression phase of aqueous humor production, and

in an amount effective in treatment of ocular **hypertension**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 37 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1993:617439 CAPLUS
DOCUMENT NUMBER: 119:217439
TITLE: Treatment of ocular **hypertension** with beta-blockers and derivatives of prostanoic acid
INVENTOR(S): Ueno, Ryuji; Kuno, Sachiko
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Japan
SOURCE: Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 561073	A1	19930922	EP 1992-307700	19920824
EP 561073	B1	20011024		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
AT 207360	E	20011115	AT 1992-307700	19920824
ES 2166353	T3	20020416	ES 1992-307700	19920824
JP 06040919	A2	19940215	JP 1993-56852	19930317
US 5432174	A	19950711	US 1993-162386	19931207
PRIORITY APPLN. INFO.:			JP 1992-63316 A	19920319
			US 1992-933789 B1	19920824

AB An agent for the treatment of ocular **hypertension** comprises (1) a .beta.-adrenergic blocker, to be administered at the enhancement phase of aq. humor prodn.; and (2) a prostanoic acid compd. (e.g. a prostaglandin compd.), to be administered at the suppression phase of aq. humor prodn. The components (1) and (2) are contained in sep. dosage forms. Prostaglandin prepn. is described, as is the effect of timolol (.beta.-adrenergic blocker) and 13,14-dihydro-15-keto-20-ethyl-PGF2.alpha. iso-Pr ester (I) (prepn. given) on change of intraocular pressure in the enhancement and suppression phases of aq. humor prodn. A formulation of timolol maleate and a formulation of I are also included.

L6 ANSWER 38 OF 45 USPATFULL on STN
ACCESSION NUMBER: 93:67608 USPATFULL
TITLE: Ocular hypotensive agents
INVENTOR(S): Ueno, Ryuzo, Nishinomiya, Japan
Ueno, Ryuji, Nishinomiya, Japan
Oda, Tomio, Sanda, Japan
PATENT ASSIGNEE(S): R-Tech Ueno Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5236907		19930817
APPLICATION INFO.:	US 1991-774750		19911011 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-414331, filed on 29 Sep 1989, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1988-248720	19881001
	JP 1988-248721	19881001

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gersil, Robert
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn Macpeak & Seas
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
LINE COUNT: 761
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to an ocular hypotensive treatment of glaucoma which comprising employing 20-substituted-PGs or 20-substituted15-keto-PGs effective as an ocular hypotensive agent; these compounds exhibit no or little side effect such as transient ocular hypertensive response, hyperemia of conjunctiva or of iris, dacryops, lema, closed eye and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 39 OF 45 USPATFULL on STN
ACCESSION NUMBER: 93:40023 USPATFULL

TITLE: Ocular hypotensive agents
INVENTOR(S): Ueno, Ryuzo, Nishinomiya, Japan
Ueno, Ryuiji, Nishinomiya, Japan
PATENT ASSIGNEE(S): R-Tech Ueno, Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5212200		19930518
APPLICATION INFO.:	US 1991-760280		19910916 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1990-584669, filed on 19 Sep 1990, now patented, Pat. No. US 5151444 which is a continuation of Ser. No. US 1988-246059, filed on 19 Sep 1988, now patented, Pat. No. US 5001153

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1987-235890	19870918
	JP 1987-334037	19871229

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gerstl, Robert
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1083
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 40 OF 45 USPATFULL on STN
ACCESSION NUMBER: 93:20525 USPATFULL
TITLE: Ocular hypotensive agents
INVENTOR(S): Ueno, Ryuzo, Nishinomiya, Japan
Ueno, Ryuji, Nishinomiya, Japan
Oda, Tomio, Sanda, Japan
PATENT ASSIGNEE(S): K.K. Ueno Seiyaku Oyo Kenkyujo, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5194429		19930316
APPLICATION INFO.:	US 1990-615515		19901119 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1989-414331, filed on 29 Sep 1989, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1988-248720	19881001
	JP 1988-248721	19881001

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Waddell, Frederick E.
ASSISTANT EXAMINER: Fay, Zohreh A.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 13
EXEMPLARY CLAIM: 1
LINE COUNT: 778
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to an ocular hypotensive composition and a composition for treatment of glaucoma which comprising an amount of

20-substituted-PGs or 20-substituted-15-keto-PGs effective as an ocular hypotensive agent; these compounds exhibit no or little side effects such as transient ocular hypertensive response, hyperemia of conjunctiva or of iris, dacryops, lema, closed eye and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 41 OF 45 USPATFULL on STN

ACCESSION NUMBER:	93:10556 USPATFULL
TITLE:	Use of 15-ketoprostaglandin E or F compounds for uterine contraction
INVENTOR(S):	Ueno, Ryuzo, Hyogo, Japan Ueno, Ryuji, Hyogo, Japan Oda, Tomio, Hyogo, Japan
PATENT ASSIGNEE(S):	K.K. Ueno Seiyaku Oyo Kenkyujo, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5185374		19930209
APPLICATION INFO.:	US 1991-687790		19910422 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1989-349548, filed on 9 May 1989, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1988-115408	19880511
	JP 1988-137666	19880602

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Schenkman, Leonard
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS:	22
EXEMPLARY CLAIM:	1
LINE COUNT:	1011

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of inducing uterine contraction which comprises administering, to a subject in need of such contraction, a uterine-contractionally effective amount of a prostanoic acid derivative selected from the group consisting of

a) 15-ketoprostaglandin E compounds, and

b) 15-ketoprostaglandin F compounds with the proviso that when the only one group, which is unsubstituted n-pentyl group, is attached to the carbon atom at the 15-position of the prostanoic acid nucleus and the bond between the carbon atoms at 5- and 6-positions is a double bond, then the bond between the carbon atoms at 13- and 14-positions is a single bond.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 42 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	1993:32951 CAPLUS
DOCUMENT NUMBER:	118:32951
TITLE:	Treatment of ocular **hypertension** with a synergistic combination of a 15-ketoprostaglandin and a carbonate dehydratase inhibitor
INVENTOR(S):	Ueno, Ryuji
PATENT ASSIGNEE(S):	Ueno Seiyaku Oyo Kenkyujo K. K., Japan
SOURCE:	Eur. Pat. Appl., 14 pp. CODEN: EPXXDW
DOCUMENT TYPE:	Patent
LANGUAGE:	English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 501678	A2	19920902	EP 1992-301412	19920220
EP 501678	A3	19921216		
EP 501678	B1	19960501		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
AT 137407	E	19960515	AT 1992-301412	19920220
ES 2089387	T3	19961001	ES 1992-301412	19920220
CA 2061907	AA	19920902	CA 1992-2061907	19920226
CA 2061907	C	20030408		
JP 05065227	A2	19930319	JP 1992-43018	19920228
JP 2511611	B2	19960703		
US 5547968	A	19960820	US 1995-487637	19950607

PRIORITY APPLN. INFO.: JP 1991-61328 A 19910301
US 1992-833025 B1 19920210
US 1993-51434 B1 19930423
US 1994-352822 B1 19941201

AB Ocular **hypertension** is treated with a compn. comprising a synergistic combination of (a) a 15-ketoprostaglandin (or salt or ester thereof) and (b) a carbonate dehydratase inhibitor in assocn. with a pharmaceutically acceptable carrier, diluent, or excipient. 13,14-Dihydro-15-keto-20-ethyl-PGA2 isoPr ester was prepd. starting with (-)-Corey lactone. The combined use of acedazolamide and isoPr (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-hept-5-enoate [13,14-dihydro-15-keto-20-ethyl-PGF2.alpha. iso-Pr ester synergistically lowered ocular pressure in rabbit eyes.

L6 ANSWER 43 OF 45 USPATFULL on STN
ACCESSION NUMBER: 92:92786 USPATFULL
TITLE: Ocular hypotensive agents
INVENTOR(S): Ueno, Ryuzo, Nishinomiya, Japan
Ueno, Ryuji, Nishinomiya, Japan
PATENT ASSIGNEE(S): K.K. Ueno Seiyaku Oyo Kenkyujo, Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5166178		19921124
APPLICATION INFO.:	US 1991-760269		19910916 (7)

RELATED APPLN. INFO.: Division of Ser. No. US 1990-584669, filed on 19 Sep 1990 which is a continuation of Ser. No. US 1988-246059, filed on 19 Sep 1988, now patented, Pat. No. US 5001153

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1987-235890	19870918
	JP 1987-334037	19871229

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Waddell, Frederick E.
ASSISTANT EXAMINER: Fay, Zohreh A.
LEGAL REPRESENTATIVE: Sughrue, Mion, Zinn, Macpeak & Seas
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1117
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to ocular hypotensive agents which contains 13,14-dihydro-15-keto-prostagrandins, which shows no transient ocular hypertensive response that PGs usually show.

AB A method for treatment of a hepatobiliary disease which comprises administering, to a subject in need of such treatment, a 15-ketoprostaglandin compound in an amount effective in treatment of the hepatobiliary disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>

US 1009008509P1

Creation date: 03-22-2004
Indexing Officer: BTEFERRA - BERIHUN TEFERRA
Team: OIPEBackFileIndexing
Dossier: 10090085

Legal Date: 09-11-2003

No.	Doccode	Number of pages
1	CTNF	6
2	892	1
3	FOR	37
4	FOR	40
5	FOR	23

Total number of pages: 107

Remarks:

Order of re-scan issued on .....